

**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
(**深圳市海普瑞藥業集團股份有限公司**)

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
(**Stock Code: 9989**)

**VOLUNTARY ANNOUNCEMENT**

**THE COMPANY'S H SHARES WILL BE NEWLY INCLUDED IN  
THE FTSE GLOBAL EQUITY INDEX SERIES**

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "**Company**"), together with its subsidiaries referred to as the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the Company's H shares will be newly included in the FTSE Global Equity Index Series ("**FTSE GEIS**") as a mid-cap index, which will become effective on December 21, 2020.

**INFORMATION ABOUT FTSE GEIS**

FTSE GEIS includes over 16,000 large, mid, small, and micro cap securities across 49 developed and emerging markets globally, with a wide range of modular indexes available to target specific markets and market segments.

Shareholders and potential investors of the **Company** are advised to exercise caution when dealing in the securities of the **Company**. The inclusion of the **Company**'s H shares in the

**Li Li**  
*Chairman*

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Sun Xiang; the non-executive director of the Company is Mr. Bu Huihua; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junde and Mr. Wang Shaohui.*